Blow for Eli Lilly as research institute deems diabetes candidate no better than competition
Eli Lilly’s type 2 diabetes candidate, tirzepatide, is no better than other diabetes drugs on the market, including Novo Nordisk’s blockbuster Ozempic, according to the Institute for Clinical and Economic Review.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
Eli Lilly’s tirzepatide – presumably the biggest competition for Novo Nordisk’s new generation of diabetes drugs – is not more effective than other type 2 diabetes treatments on the market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
.jpg&w=384&q=75)
